title: Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.
abstract: BACKGROUND
  Stenting reduces both acute complications of coronary angioplasty and restenosis rates but increases subacute thrombosis rates and hemorrhagic complications when used with coumadin anticoagulation.
  
  
  RESULTS
  To simplify postcoronary stenting treatment and to reduce these drawbacks, we evaluated the 1-month outcome of a prospective registry of 2900 patients in whom successful coronary artery stenting was performed without coumadin anticoagulation. Patients received 100 mg/d aspirin and 250 mg/d ticlopidine for 1 month. Low-molecular-weight heparin (LMWH) treatment was progressively reduced in four consecutive stages, from 1-month treatment to none. Event-free outcome at 1 month was achieved in 2816 patients (97.1%). Major stent-related cardiac events were subacute closure in 51 patients (1.8%), including death in 12 (0.5%), acute myocardial infarction in 17 (0.6%), and coronary artery bypass graft surgery in 9 (0.3%). Stent thrombosis was more frequent with balloon size of < 3.0 mm (< or = 2.5 mm, 10%; 3.0 mm, 2.3%; > or = 3.5 mm, 1.0%; P < .001), bail-out situations (6.67% versus 1.38%, P < .001), and patients with unstable angina or acute myocardial infarction (2.2% versus 1.12%, P = .02). Bleeding complications that required transfusion, surgical repair, or both occurred in 55 patients (1.9%). Bleeding complications were related to female gender (4.0% versus 1.51%, P < .001), duration of LMWH treatment (3.83% in phase II/III versus 0.69% in phase IV/V, P < .001), sheath size (6F, 0.52%; 7F, 1.04%; > or = 8F, 4.23%; P < .001), bail-out situations (4.76% versus 1.67%, P < .01), and saphenous graft stenting (4.38% versus 1.75%, P = .04).
  
  
  CONCLUSIONS
  These results suggest that poststenting treatment by ticlopidine/aspirin is an effective alternative to coumadin anticoagulation, achieving low rates of subacute closure and bleeding complications. LMWH treatment does not improve subacute reocclusion rates but increases bleeding complications. Furthermore, as bleeding complications were independently related to sheath size, we suggest that stenting with 6F guiding catheters may prevent local complications. Furthermore, the ticlopidine/aspirin combination allows a low-cost stenting strategy without ultrasound assessment of stent deployment and permits short inhospital stay.
authors.affiliation: Institut Cardiovasculaire Paris-Sud, Clinique du Bois de Verrières, Antony, France.
authors.forename: G J
authors.initials: GJ
authors.lastname: Karrillon
authors.forename: M C
authors.initials: MC
authors.lastname: Morice
authors.forename: E
authors.initials: E
authors.lastname: Benveniste
authors.forename: P
authors.initials: P
authors.lastname: Bunouf
authors.forename: P
authors.initials: P
authors.lastname: Aubry
authors.forename: S
authors.initials: S
authors.lastname: Cattan
authors.forename: B
authors.initials: B
authors.lastname: Chevalier
authors.forename: P
authors.initials: P
authors.lastname: Commeau
authors.forename: A
authors.initials: A
authors.lastname: Cribier
authors.forename: C
authors.initials: C
authors.lastname: Eiferman
authors.forename: G
authors.initials: G
authors.lastname: Grollier
authors.forename: Y
authors.initials: Y
authors.lastname: Guerin
authors.forename: M
authors.initials: M
authors.lastname: Henry
authors.forename: T
authors.initials: T
authors.lastname: Lefevre
authors.forename: B
authors.initials: B
authors.lastname: Livarek
authors.forename: Y
authors.initials: Y
authors.lastname: Louvard
authors.forename: J
authors.initials: J
authors.lastname: Marco
authors.forename: S
authors.initials: S
authors.lastname: Makowski
authors.forename: J P
authors.initials: JP
authors.lastname: Monassier
authors.forename: J M
authors.initials: JM
authors.lastname: Pernes
authors.forename: P
authors.initials: P
authors.lastname: Rioux
authors.forename: C
authors.initials: C
authors.lastname: Spaulding
authors.forename: G
authors.initials: G
authors.lastname: Zemour
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003331:Coronary Vessels; D005260:Female; D005602:France; D006470:Hemorrhage / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D012042:Registries; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014465:Ultrasonics
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin